Asterias Biotherapeutics, Inc. (NYSEMKT:AST) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure
On November 17, 2016, Asterias Biotherapeutics, Inc. (the
Company) posted a PowerPoint presentation on its website to
utilize for investor relation purposes. The presentation is
furnished herewith as Exhibit 99.1.
The information in this Item 7.01 and Item 9.01(d) is being
furnished and shall not be deemed to be filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended
(the Exchange Act), or otherwise subject to the liabilities of
that section, nor shall such exhibits be deemed incorporated by
reference in any filing made by the Company under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly
set forth by specific reference in such a filing.
Item 9.01 Financial Tables and Exhibits.
About Asterias Biotherapeutics, Inc. (NYSEMKT:AST)
Asterias Biotherapeutics, Inc. is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors. The second is pluripotent stem cell platform. Pluripotent cells are a type of stem cell capable of becoming all of the cell types in the human body. From its immunotherapy platform, the Company is developing over two programs. AST-VAC1 (telomerase loaded, autologous dendritic cells), which allows patient’s own cells to recognize and fight cancer cells in acute myelogenous leukemia (AML). Together with Cancer Research United Kingdom (CRUK), it is developing AST-VAC2 (telomerase loaded, -allogeneic dendritic cells), -derived from pluripotent stem cells. From its pluripotent stem cell platform, it is developing AST-OPC1, oligodendrocyte progenitor cells. Asterias Biotherapeutics, Inc. (NYSEMKT:AST) Recent Trading Information
Asterias Biotherapeutics, Inc. (NYSEMKT:AST) closed its last trading session up +0.40 at 4.80 with 153,947 shares trading hands.